Is Outlook Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges.
In comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued.